Bio-Techne

Spear Bio is a biotechnology company based in Weston, Massachusetts, founded in 2021. The company specializes in ultrasensitive protein detection technology, which significantly enhances healthcare diagnostics. Its innovative approach enables the quantification of minute protein biomarkers from samples collected at home, facilitating self-testing and telemedicine applications. By allowing clinicians to detect these biomarkers from small sample volumes, Spear Bio's technology integrates seamlessly into existing workflows for sample collection, processing, and detection, thereby improving the overall efficiency of healthcare delivery.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

Wilson Wolf Corporation, founded in 1998, specializes in the design and manufacture of innovative cell culture devices aimed at advancing healthcare solutions. The company develops a range of products for diverse applications such as monoclonal antibody production, living skin, corneal storage, islet transplants for type 1 diabetes, and immunotherapy. Their revolutionary gas permeable cell culture device platform serves as an alternative to traditional methods like plates, flasks, and bags, providing enhanced options for scientists and businesses engaged in cell culture. Wilson Wolf is committed to contributing to medical advancements, particularly in cancer treatment and regenerative medicine.

Namocell Inc., established in 2014 and headquartered in Mountain View, California, specializes in developing, manufacturing, and distributing innovative microfluidic-based platforms for life science research and clinical applications. The company focuses on single-cell enriching, sorting, and analysis technologies, catering to biotech industry researchers and scientists. Its products aim to streamline various applications such as cell line development, cancer diagnostics, immunotherapy, and single-cell genomics, while being user-inspired and gentle on cells to preserve viability and integrity.

Asuragen, Inc. is a molecular diagnostics company based in Austin, Texas, specializing in oncology and genetic disorders. Founded in 2005, the company develops and commercializes a diverse array of diagnostic products and services aimed at improving patient management. Its offerings include various AmplideX reagents for detecting genetic markers, as well as comprehensive cancer diagnostic kits, such as QUANTIDEX and Signature assays that target specific mutations and gene fusions. Asuragen employs its patented Armored RNA technology in its diagnostics portfolio, which encompasses genetic and oncology testing products alongside industry-leading controls. The company also provides GLP testing services and operates a cGMP manufacturing facility, ensuring a seamless process from discovery to commercialization. With a focus on enhancing treatment outcomes through precise data, Asuragen plays a critical role in the medical community's efforts to improve patient care in oncology and genetics.

Eminence specializes in the development and manufacturing of chemically-defined media for cell culture, particularly focusing on CHO (Chinese Hamster Ovary) cells. The company has created proprietary products such as EmCD CHO® basal medium and EmCD CHO® Feed, which are designed for various CHO cell lines, including CHO-K1, CHO-S, and CHO-DG44. Eminence offers a comprehensive range of services, including medium formulation development and optimization, tailored to meet the specific needs of its clients in the biopharma sector. With a skilled research and development team and GMP-compliant production facilities, Eminence is committed to delivering high-quality products and flexible solutions, supporting biopharmaceutical companies in adhering to stringent safety and efficacy standards in their processes.

B-MoGen Biotechnologies, based in Saint Paul, Minnesota, specializes in providing tailored gene editing solutions since 2015. The company offers custom vector generation services using the Sleeping Beauty transposon system for multi-gene expression vectors, along with custom gene targeting vectors. Their genome modification services encompass gene knockout, knock-in, and stable cell line generation. B-MoGen's products include Sleeping Beauty transposon and transposase vectors, available through Neuromics. As a subsidiary of Bio-Techne Corporation since 2019, the company serves both academic and industrial clients, leveraging strategic partnerships and proprietary intellectual property in genome engineering.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Quad Technologies is disrupting cell separation and cell therapy workflows by providing researchers with a simple, cell-friendly capture and release technology for cell isolation. Their new MagCloudz™ Streptavidin Cell Separation kit, featuring novel QuickGel™ technology platform, enables straightforward, scalable and fast cell separation with unique magnetic particle dissociation, resulting in complete label free cells. For applications such as T Cell purification, stem cell isolation, circulating tumor cell (CTC) separation and immunotherapy, this unique solution offers drastically improved cell viability, purity and recovery while maintaining a native cellular phenotype.

Astute Medical, Inc. is a life science tools company focused on improving the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers. Founded in 2007 and based in San Diego, California, with an additional location in Paris, France, the company specializes in creating novel diagnostic tests that enable rapid diagnosis and risk assessment for conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Astute Medical's flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers associated with acute kidney injury, while the Astute140 meter converts the test's fluorescent signal into a single numerical result. The company markets its products primarily in the United States and Europe and operates as a subsidiary of bioMérieux S.A.

Advanced Cell Diagnostics, Inc. is a biotechnology company specializing in the development and commercialization of cell and tissue-based diagnostic tests for personalized medicine. Founded in 2007 and based in Hayward, California, the company utilizes its proprietary RNAscope technology, a multiplex fluorescent and chromogenic in situ hybridization platform, to detect and quantify RNA biomarkers at single molecule sensitivity. Its product offerings include RNAscope manual assays and reagent kits, automated tissue staining solutions, catalog probes, and software for quantitative analysis of RNA in situ hybridization samples. Advanced Cell Diagnostics also provides pharmaceutical assay services to aid in understanding disease mechanisms and support preclinical and clinical research, including companion diagnostic assay development. The company serves a global market through a network of distributors in various countries and has a direct online presence.

Space Import Export S.r.l. is a distribution company that has been working in the Life Science business since 1985, specialized in the fields of Biomedical Research and Diagnostic Market. Our distribution activity has grown, through an active cooperation with a sister company, called LaboSpace, provider of laboratory services, with branches in Italy, UK and USA.

Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in developing and commercializing innovative tools for protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. By utilizing microfluidics technology, the scWestern system partitions single cells into micro-wells, lyses them, and performs SDS-PAGE separation on each cell lysate. This technology facilitates the identification of cellular subpopulations, the analysis of enriched cell populations post-FACS sorting, and studies on cell signaling and cancer heterogeneity, among other applications. Researchers leverage Zephyrus's products to gain deeper insights into various biological fields, including cancer, stem cells, neurology, and human disease development, ultimately aiming to enhance healthcare outcomes.

CLINIQA Corp specializes in the manufacturing and commercialization of quality controls and calibrators for the in vitro diagnostics (IVD) industry. With over 40 years of experience, the company has established a reputation for producing high-quality products that enhance the accuracy of diagnostic tests. CLINIQA operates from facilities in San Diego County, California, and adheres to stringent quality management systems that comply with FDA regulations and international standards. The company offers a range of products, including reagents, controls, calibrators, proficiency test materials, and contract manufacturing services. Notably, its Liquid QC® products provide "ready-to-use" solutions with extended shelf life and stability, addressing market demands for convenience and reproducibility. CLINIQA's commitment to quality and focus on liquid stabilization technology underpins its success in meeting the needs of the diagnostic sector.

CyVek, Inc., established in 2008 and headquartered in Wallingford, Connecticut, specializes in developing a platform technology for measuring analytes in biological samples. The company offers an integrated test system comprising a microfluidic cartridge that enables the analysis of multiple biomarkers from minimal amounts of biological samples.

Novus Biologicals, LLC is dedicated to accelerating scientific discovery by developing and marketing specialized products for the life sciences sector. The company offers a diverse range of research tools, including primary and secondary antibodies, peptides, proteins, kits, controls, lysates, and RNAi, which aid researchers in studying protein functions across various fields such as cancer, neuroscience, autophagy, and cardiovascular research. By focusing on niche and emerging markets, Novus Biologicals meets the needs of the biological research community, providing access to unique biological materials and ongoing technical support. The company actively monitors scientific trends to ensure the availability of relevant materials, thereby playing a vital role in advancing biological research and fostering strong partnerships with customers.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Shanghai PrimeGene Bio-Tech Company is a prominent player in the Chinese biotechnology sector, specializing in the development, manufacture, and distribution of recombinant proteins tailored for research and diagnostic applications. Based in Shanghai, the company provides a diverse array of high-quality recombinant proteins and related antibodies, catering primarily to bio-reagent companies. Its offerings include recombinant proteins, recombinant antigens for diagnostics, and essential proteins such as protein A, protein G, and protein L. Additionally, Shanghai PrimeGene Bio-Tech engages in gene cloning, synthesis, and gene expression in various systems, including E. coli and yeast, reinforcing its commitment to advancing research and diagnostic capabilities in the biotechnology field.

CyVek, Inc., established in 2008 and headquartered in Wallingford, Connecticut, specializes in developing a platform technology for measuring analytes in biological samples. The company offers an integrated test system comprising a microfluidic cartridge that enables the analysis of multiple biomarkers from minimal amounts of biological samples.

Bionostics is a world-leading developer and manufacturer of high quality, turnkey calibrators and quality control products for original equipment manufacturers (OEMs) for critical care / point-of-care and diabetes diagnostics test systems. Located in Devens, Massachusetts, Bionostics offers a variety of services to provide high quality, cost effective, turn-key solutions to our customers, large and small. We maintain professional associations with customers and suppliers, striving to work together in relationships that are beneficial for all parties. As a key partner to world-class OEMs, we are acutely aware of our responsibility to maintain and foster the brand identities of our clients. Our quality systems are certified to ISO 9001:2008 and 13485:2003. Our products are listed as Class I and Class II with the US FDA, bear Class II and Class III Medical Device Licenses in Canada and fully comply with requirements of 98/79/EC, the In-Vitro Diagnostics Directive.

Tocris Holdings is a supplier of reagents for non-clinical life science research.

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focusing on the development and commercialization of innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company specializes in orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors, aiming to inhibit the inappropriate immune responses associated with various diseases. Its lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently in Phase III development for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and in Phase IIb trials for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing several other candidates, including CCX140, an inhibitor targeting the CCR2 receptor for diabetic nephropathy and focal segmental glomerulosclerosis, and CCX872, a selective CCR2 inhibitor in Phase Ib trials for advanced pancreatic cancer. Founded in 1996, ChemoCentryx continues to drive innovation in targeted therapies for rare and complex diseases.